Asset Details
Do you wish to reserve the book?
D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity
Do you wish to request the book?
D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity
2023
Overview
D‐1553 is a small molecule inhibitor selectively targeting KRASG12C and currently in phase II clinical trials. Here, we report the preclinical data demonstrating antitumor activity of D‐1553. Potency and specificity of D‐1553 in inhibiting GDP‐bound KRASG12C mutation were determined by thermal shift assay and KRASG12C‐coupled nucleotide exchange assay. In vitro and in vivo antitumor activity of D‐1553 alone or in combination with other therapies were evaluated in KRASG12C mutated cancer cells and xenograft models. D‐1553 showed selective and potent activity against mutated GDP‐bound KRASG12C protein. D‐1553 selectively inhibited ERK phosphorylation in NCI‐H358 cells harboring KRASG12C mutation. Compared to the KRAS WT and KRASG12D cell lines, D‐1553 selectively inhibited cell viability in multiple KRASG12C cell lines, and the potency was slightly superior to sotorasib and adagrasib. In a panel of xenograft tumor models, D‐1553, given orally, showed partial or complete tumor regression. The combination of D‐1553 with chemotherapy, MEK inhibitor, or SHP2 inhibitor showed stronger potency on tumor growth inhibition or regression compared to D‐1553 alone. These findings support the clinical evaluation of D‐1553 as an efficacious drug candidate, both as a single agent or in combination, for patients with solid tumors harboring KRASG12C mutation. D‐1553 is a novel and potent inhibitor of KRASG12C. D‐1553 shows an inhibitory effect on the RAS–MEK signaling pathway. D‐1553 has antitumor activity in vitro and in in vivo models with KRASG12C mutation.
